Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $783.8552W HIGH $1,292.65
Volume
1.39 M
Value Traded
3.68 B
Short % Float
0.89%
+3.16%Week
+5.01%1 Month
-0.22%3 Month
+26.86%6 Month
+432.5%5 Year
+37,819.33%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
1110.11 B
EPS (TTM)
29.97
P/E Ratio
39.35
Ent. Value
1149.02 B
Total Shares
940.94 M
Float Shares
848.42 M
Insiders
9.87%
Institutions
76.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
LLY Catalyst Timeline
Dated clinical, regulatory and corporate events for Eli Lilly and Company
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eli Lilly and Company
2673Total events
55Upcoming
1119Tier-1 (high impact)
2011 to 2040Coverage
Upcoming catalysts 2
Event history 50
▲Additional DataZepboundApprovedClinical Data
Exploratory biomarker data for Zepbound used concomitantly with Taltz in TOGETHER-PsO
moderate-to-severe plaque psoriasis and obesity or overweightsource ↗
▲Additional DataIxekizumabApprovedClinical Data
Exploratory biomarker data from TOGETHER-PsO presented at Fall Clinical 2026
moderate-to-severe plaque psoriasis and obesity or overweightsource ↗
◆Poster PresentationLebrikizumabApprovedPresentation
Lebrikizumab impact on alleviating disease severity, itch burden and quality of life in patients with moderate-to-severe atopic dermatitis: 16-week interim results from a European prospective observational study (ADtrust)
moderate-to-severe atopic dermatitissource ↗
◆Poster PresentationEloralintideApprovedPresentation
Concomitant treatment with ixekizumab and tirzepatide according to demographics and disease characteristics for patients with psoriasis and overweight or obesity: Subgroup analyses from the TOGETHER-PsO randomized trial
psoriasis and overweight or obesitysource ↗
◆Poster PresentationBaricitinibApprovedPresentation
Baricitinib provides sustained efficacy through 1.5 years and consistent safety up to a maximum of 2.5 years of treatment in adolescents with severe alopecia areata: BRAVE-AA-PEDS trial results
severe alopecia areatasource ↗
◆Poster PresentationIxekizumabApprovedPresentation
Ixekizumab plus tirzepatide reduced CV risk factors vs ixekizumab alone
psoriatic disease and obesitysource ↗
▲FDA ApprovalPirtobrutinibApprovedFDA Decision
FDA approves expanded indication for Jaypirca in previously untreated CLL/SLL
previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletionsource ↗
▲Full ResultsOrforglipronApprovedClinical Data
Post-hoc analyses of ATTAIN-1 published showing reductions in predicted 10-year type 2 diabetes and cardiovascular disease risk
Obesity or overweight with a weight-related medical problemsource ↗
▲PublicationOrforglipronApprovedPresentation
Post-hoc analyses of ATTAIN-1 published in Diabetes, Obesity and Metabolism
Obesity or overweight with a weight-related medical problemsource ↗
▲Primary Endpoint MetEBGLYSSApprovedClinical Data
ADtouch primary endpoint met: 53% vs 27% placebo achieved HF-IGA 0/1 at Week 16
moderate-to-severe hand and foot atopic dermatitissource ↗
◆Late-BreakerEBGLYSSApprovedPresentation
ADtouch late-breaking results to be presented at EADV Congress
moderate-to-severe hand and foot atopic dermatitissource ↗
▲Topline ReadoutEBGLYSSApprovedClinical Data
EBGLYSS Phase 3b ADtouch topline results announced
moderate-to-severe hand and foot atopic dermatitissource ↗
▲Topline ReadoutEloraTZPClinical Data
Lilly announced positive Phase 2b results for EloraTZP in obesity/overweight with type 2 diabetes
obesity or overweight and type 2 diabetessource ↗
▲Primary Endpoint MetEloraTZPClinical Data
EloraTZP met primary endpoint of percent change in body weight vs placebo at 48 weeks
obesity or overweight and type 2 diabetessource ↗
▲Oral PresentationEloraTZPPresentation
Phase 2b EloraTZP results presented at the 62nd Annual Meeting of EASD in Milan, Italy
obesity or overweight and type 2 diabetessource ↗
◆Oral PresentationEBGLYSSApprovedPresentation
Almirall to present five-year ADlong results at EADV
moderate-to-severe atopic dermatitissource ↗
▲Topline ReadoutOrforglipronApprovedClinical Data
Lilly announced detailed Phase 3 ACHIEVE-4 results for Foundayo (orforglipron) vs insulin glargine
type 2 diabetes with obesity or overweight at increased cardiovascular risksource ↗
▲Primary Endpoint MetOrforglipronApprovedClinical Data
ACHIEVE-4 met primary objective of non-inferiority for MACE-4 vs insulin glargine
type 2 diabetes with obesity or overweight at increased cardiovascular risksource ↗
▲Oral PresentationOrforglipronApprovedPresentation
ACHIEVE-4 results presented at 62nd Annual Meeting of EASD in Milan, Italy
type 2 diabetes with obesity or overweight at increased cardiovascular risksource ↗
▲PublicationOrforglipronApprovedPresentation
ACHIEVE-4 results simultaneously published in The Lancet
type 2 diabetes with obesity or overweight at increased cardiovascular risksource ↗
▲FDA ApprovalOnswikApprovedFDA Decision
FDA approves Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes
type 2 diabetessource ↗
▲Grant / FundingCorporate
$12.5 million support to San Jacinto College for manufacturing talent pipeline
▲Manufacturing MilestoneOrforglipronApprovedCMC / Inspection
Lilly breaks ground on $6.5B Houston API manufacturing site
◆Poster PresentationOrforglipronApprovedPresentation
ATTAIN-1 Physical and Psychosocial Functioning data for Foundayo presented at EASD 2026
obesity or overweight with at least one weight-related medical problemsource ↗
◆Poster PresentationZepboundApprovedPresentation
SURMOUNT-5 Exploratory Proteomic Findings for Zepbound presented at EASD 2026
obesity or overweightsource ↗
◆Poster PresentationMounjaroApprovedPresentation
SURPASS-EARLY Pre-Specified Analysis for Mounjaro presented at EASD 2026
early type 2 diabetessource ↗
◆Poster PresentationEloraTZPPresentation
EloraTZP Phase 1 results presented at EASD 2026
obesity or overweightsource ↗
◆Oral PresentationOrforglipronApprovedPresentation
Foundayo ACHIEVE-2/ACHIEVE-3 time-to-goal analysis presented at EASD 2026
type 2 diabetessource ↗
▲Oral PresentationEloraTZPPresentation
Phase 2b EloraTZP results presented at the 62nd Annual Meeting of EASD in Milan, Italy
obesity or overweight and type 2 diabetessource ↗
▲Full ResultsIxekizumabApprovedClinical Data
52-week results from TOGETHER-PsO announced
psoriatic disease and obesitysource ↗
▲Full ResultsZepboundApprovedClinical Data
52-week results from TOGETHER-PsA announced
psoriatic disease and obesitysource ↗
▲FDA ApprovalMounjaroApprovedFDA Decision
FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes
type 2 diabetes with high cardiovascular risksource ↗
●Full ResultsMounjaroApprovedClinical Data
Full results from SURPASS-CVOT published in NEJM
type 2 diabetes with established atherosclerotic cardiovascular diseasesource ↗
▲Primary Endpoint MetMounjaroApprovedClinical Data
SURPASS-CVOT met primary endpoint of non-inferiority vs Trulicity for MACE-3
type 2 diabetes with atherosclerotic cardiovascular diseasesource ↗
●Other Regulator MilestoneMounjaroApprovedEx-US Regulatory
SURPASS-CVOT data included in Mounjaro product information in the European Union
type 2 diabetessource ↗
▲RWE DataZepboundApprovedClinical Data
Real-world study shows Zepbound lowers healthcare costs in adults over 55
obesitysource ↗
▲IP Litigation RulingRetatrutideIP / Competition
Lilly files six new lawsuits against U.S. entities selling black-market retatrutide
●Quarterly UpdateCorporate
Lilly reports Q2 2026 financial results with revenue of $23.0 billion, EPS of $7.94
▲FDA ApprovalEBGLYSSApprovedFDA Decision
FDA approves Ebglyss for one maintenance dose every eight weeks in moderate-to-severe atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
▲EU ApprovalPirtobrutinibApprovedEx-US Regulatory
European Commission approves Jaypirca as monotherapy for adults with CLL across all lines of therapy
chronic lymphocytic leukemiasource ↗
●NDA SubmissionOrforglipronApprovedRegulatory Filing
Submission for orforglipron for type 2 diabetes in the U.S.
type 2 diabetessource ↗
▲Topline ReadoutRetatrutideClinical Data
Retatrutide drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea
obesity and complicationssource ↗
▲AcquiredCorporate
Completed acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics
▲Breakthrough Therapy DesignationOlomorasibDesignation
FDA grants Breakthrough Therapy designation to olomorasib for previously treated KRAS G12C-mutant advanced pancreatic cancer
KRAS G12C-mutant advanced pancreatic cancersource ↗
▲Topline ReadoutPirtobrutinibApprovedClinical Data
Jaypirca significantly reduced risk of disease progression or death by 45% when added to venetoclax time-limited regimen in previously treated CLL/SLL
CLL/SLLsource ↗
▲Topline ReadoutOrforglipronApprovedClinical Data
Foundayo and lower-dose Zepbound helped maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
weight maintenancesource ↗
▲Topline ReadoutSelpercatinibApprovedClinical Data
Retevmo demonstrated 83% reduction in risk of disease recurrence or death as adjuvant therapy
early-stage RET fusion-positive lung cancersource ↗
▲Topline ReadoutVERVE-102Clinical Data
Single dose of VERVE-102 reduced PCSK9 by up to 88% and LDL-C by up to 62%
hypercholesterolemiasource ↗
Past FDA Catalysts and PDUFA Decisions
How LLY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-08 | Olumiant (baricitinib) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A93 / 100
Pipeline Score
$97.2B
Pipeline Value
$341.0B
Commercial Value
Richly Valued
Valuation Signal
165
Drugs Scored
0.1x
rNPV / MCap
Top 1%
Large Pharma(rank 1 of 660)
Percentile Rank
Eli Lilly and Company earns an A-grade pipeline score (93/100), with $97.2B risk-adjusted pipeline value, led by Baricitinib in Diabetes Mellitus, Type 1 (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $79.7B x 4.3 = $341.0B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Mounjaro | $32.5B | $15.7B | +107.4% |
| Zepbound | $16.9B | $8.9B | +91.2% |
| Verzenio | $5.9B | $5.6B | +5% |
| Trulicity | $4.2B | $4.7B | -10.8% |
| Jardiance | $4.1B | $3.6B | +13.5% |
| Taltz | $3.5B | $3.4B | +2.9% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Orforglipron Small moleculeNCT07153471 | Osteoarthritis | Phase 3 | ACTIVE NOT_RECRUITING | 800 | May 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every LLY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Taltz and Zepbound | psoriasis and obesity | Phase 3b | 2026-10-09 | differentially expressed proteins: 482 vs. 140; differentially expressed genes: 467 vs. 16Read More | New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesityRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jonsson PatrikOfficer (EVP & President, LLY Int'l) | Sell | -6,500 54,146.62 held | $1,175.10 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LLY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 5.7 % (32.6 %) | 309.33 M | 257.90 K | 8.91% ( 21.10 K) |
LLY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2028-12-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LLY ranks across every disease it competes in
Competitive Position is a premium feature
See how LLY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLLY News
LLY▲ +0.6%today
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Eli Lilly presented new data from the TOGETHER-PsO Phase 3b trial, showing that the combination of Taltz and Zepbound leads to broader biomarker changes compared to Taltz alone in patients with psoriasis and obesity. The findings suggest a significant immunometabolic relationship, supporting a more integrated treatment approach. The study highlights the potential for improved patient outcomes in managing both conditions.
Read more →LLYLilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
Eli Lilly will present 21 new data presentations at the Fall Clinical Dermatology Conference 2026, focusing on its dermatology portfolio. Key highlights include findings on EBGLYSS for atopic dermatitis, Taltz and Zepbound for psoriasis and obesity, and long-term outcomes for Olumiant in alopecia areata. The data aims to enhance understanding and treatment of chronic skin conditions.
Read more →LLYLilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval for an expanded indication, allowing its use as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without known 17p deletion. This decision is based on the positive results from the BRUIN CLL-313 clinical trial, which demonstrated significant improvements in progression-free survival compared to standard chemoimmunotherapy. The approval highlights Jaypirca's role in the treatment continuum for CLL/SLL.
Read more →LLYLilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Eli Lilly announced that its oral GLP-1 medication, Foundayo, demonstrated significant reductions in the predicted long-term risks of type 2 diabetes and cardiovascular disease in adults with obesity or overweight. The findings, derived from post-hoc analyses of the ATTAIN-1 trial, suggest that Foundayo could be a valuable treatment option, potentially reducing healthcare costs linked to obesity. The results were published in Diabetes, Obesity and Metabolism.
Read more →LLYLilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Eli Lilly's Phase 3 ACHIEVE-4 trial of Foundayo (orforglipron) showed significant cardiovascular safety and efficacy in type 2 diabetes patients. The study revealed a 16% lower risk of major adverse cardiovascular events compared to insulin glargine, alongside notable reductions in A1C and body weight. Foundayo also demonstrated a lower risk of cardiovascular and all-cause death, highlighting its potential as a treatment option.
Read more →LLYNew Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has shown promising results in a Phase 3b study for treating moderate-to-severe hand and foot atopic dermatitis. The study reported that over 53% of patients achieved clear or almost clear skin by Week 16, with significant improvements in itch and pain relief. Additionally, nearly 80% of patients expressed satisfaction with their treatment outcomes. These findings will be presented at the EADV Congress.
Read more →LLYLilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Eli Lilly announced positive results from a Phase 2b trial of EloraTZP, a combination of eloralintide and tirzepatide, showing greater weight loss and A1C reduction compared to tirzepatide alone. Participants lost an average of 54.1 lbs and lowered A1C by 2.9% over 48 weeks. Lilly plans to initiate Phase 3 trials by the end of 2026.
Read more →LLYLilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Eli Lilly announced promising results from the Phase 3 TRIUMPH-2 trial of retatrutide, a triple hormone receptor agonist, showing significant weight loss and A1C reduction in participants with obesity and type 2 diabetes. Over 80 weeks, participants lost an average of 49.6 lbs, with many no longer classified as obese. The drug also demonstrated improvements in cardiovascular risk factors, indicating its potential as a treatment option.
Read more →LLYLilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
Eli Lilly's Zepbound (tirzepatide) demonstrated superior weight loss compared to Wegovy HD (semaglutide) in a recent analysis. The study indicated that Zepbound 15 mg led to a 4.5% greater reduction in body weight and significantly increased the odds of achieving a 20% weight loss. These results were presented at the EASD Annual Meeting and support the efficacy of Zepbound in obesity treatment.
Read more →LLYLilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Eli Lilly announced that Foundayo (orforglipron) 17.2 mg demonstrated significantly greater weight loss and A1C reduction compared to oral semaglutide 25 mg in adults with type 2 diabetes. This conclusion is based on an indirect treatment comparison utilizing data from the ACHIEVE-3 and PIONEER PLUS studies. The findings were presented at the EASD Annual Meeting in Milan, highlighting Foundayo's potential as a foundational therapy for managing type 2 diabetes.
Read more →LLYLilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
Eli Lilly has launched the Lilly Change the Course Commitment, aiming to provide equal access to its diabetes and obesity medicines in low- and middle-income countries (LMICs) by 2040. The initiative focuses on registering innovative treatments and strengthening health systems to address significant access gaps. This commitment builds on the success of the previous Lilly 30x30 initiative, which exceeded its target of helping 30 million people by 2025.
Read more →LLYFDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
The FDA has approved Eli Lilly's Olumiant (baricitinib) for pediatric patients aged 12 and older with severe alopecia areata. This approval is based on the BRAVE-AA-PEDS study, demonstrating significant hair regrowth and safety consistent with adult usage. The treatment offers a much-needed option for adolescents facing severe hair loss, impacting their social and personal lives.
Read more →LLYU.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
Eli Lilly's Onswik (insulin efsitora alfa-gobe) has received FDA approval as a once-weekly basal insulin for adults with type 2 diabetes. This new treatment aims to simplify diabetes management by significantly reducing the number of injections required annually. The approval is based on the QWINT Phase 3 clinical trials, which showed comparable efficacy and safety to existing daily insulins. Onswik is expected to enhance patient flexibility in managing their condition.
Read more →LLYLilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
Eli Lilly has commenced construction on a new $6.5 billion manufacturing facility in Houston, Texas, aimed at producing active pharmaceutical ingredients, including Foundayo, a GLP-1 receptor agonist. This site is part of Lilly's broader initiative to reshore medicine production and is expected to create over 600 high-wage jobs. The investment also includes a partnership with San Jacinto College to develop a skilled workforce.
Read more →LLYU.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
The U.S. FDA has approved Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. This approval is based on the Phase 3 EMBER-3 trial, which demonstrated that the combination therapy significantly improves median progression-free survival. The treatment offers a new option for patients experiencing disease progression after prior endocrine therapy.
Read more →LLYLilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Eli Lilly will present new data on its cardiometabolic health portfolio at EASD 2026, highlighting pivotal results from the TRIUMPH-2 study for retatrutide, which showed significant weight loss and A1C improvements. Additionally, findings from the ACHIEVE-4 study reaffirmed Foundayo's safety and potential cardiovascular benefits. Lilly aims to expand treatment options for diabetes and obesity.
Read more →LLYLilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Eli Lilly has successfully completed its acquisition of AtaiBeckley Inc., a company focused on developing rapid-acting neuroplastogens for mental health conditions, particularly treatment-resistant depression. This acquisition aims to advance innovative therapies that could provide new treatment options for patients. The transaction received shareholder approval, highlighting confidence in the potential benefits of the merger.
Read more →LLYLilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
Eli Lilly and Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, the executive vice president, will engage in a fireside chat at 1:50 p.m. Eastern time. A live audio webcast will be available on Lilly's investor website, along with a replay for 90 days.
Read more →LLYLilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
Eli Lilly has announced its acquisition of Merida Biosciences for up to $2.875 billion to enhance its immunology portfolio. Merida's lead candidate, MER511, is in Phase 1 trials targeting Graves' disease and thyroid eye disease, showing promising initial results. The acquisition aims to address serious autoimmune and allergic diseases with a precision approach that selectively removes pathogenic autoantibodies.
Read more →LLYNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Eli Lilly announced positive results from the TOGETHER-PsO and TOGETHER-PsA Phase 3b trials, demonstrating that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) maintained or improved disease activity in adults with psoriatic disease and obesity over 52 weeks. The trials showed statistically superior outcomes compared to Taltz alone, with improvements in systemic inflammation and metabolic health. No new safety concerns were reported, supporting the efficacy of this combined treatment approach.
Read more →About Eli Lilly and Company
HeadquartersLILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285
BIOPHARMAWATCH ELITE PLUS
Trade the next LLY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime